Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...
<shortened url>
i guess ccsvi is a"threat"
Multiple Sclerosis Market Forecast
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1557 Views
-
Last post by frodo
-
- 0 Replies
- 1620 Views
-
Last post by frodo
-
- 1 Replies
- 1827 Views
-
Last post by frodo
-
- 0 Replies
- 1766 Views
-
Last post by frodo
-
- 0 Replies
- 3617 Views
-
Last post by frodo
-
- 0 Replies
- 2207 Views
-
Last post by frodo
-
- 0 Replies
- 1866 Views
-
Last post by NHE
-
- 0 Replies
- 1245 Views
-
Last post by frodo
-
- 0 Replies
- 1402 Views
-
Last post by frodo